Share
))
Join hosts Dylan Lewis, Deidre Woollard, Ricky Mulvey, and Mary Long as they cover the day’s top business news and financial headlines with the Motley Fool's team of investment analysts. Tune in on weekends for the greatest investing classes you never got the chance to take in school and perspectives from special guests helping to shape the future.
…
continue reading
Healthcare: 3 Genomics Stocks Revolutionizing Healthcare And Why Alnylam's New Deal Didn't Excite Investors
Manage episode 231061070 series 2394758
Content provided by The Motley Fool. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Motley Fool or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Here's why a $1 billion deal with Regeneron failed to spark a rally in Alnylam shares. Also, will genetic discovery be our generation's biggest trend? If so, Illumina, bluebird bio, and Invitae could be top stocks to watch.
Check out more of our content here:
2043 episodes
